Forvis Mazars Wealth Advisors LLC Has $3.18 Million Stock Holdings in Incyte Co. (NASDAQ:INCY)

Forvis Mazars Wealth Advisors LLC boosted its holdings in shares of Incyte Co. (NASDAQ:INCY) by 8.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 46,003 shares of the biopharmaceutical company’s stock after buying an additional 3,453 shares during the period. Forvis Mazars Wealth Advisors LLC’s holdings in Incyte were worth $3,177,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of INCY. Global X Japan Co. Ltd. boosted its stake in shares of Incyte by 144.7% during the 4th quarter. Global X Japan Co. Ltd. now owns 389 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 230 shares during the period. Brooklyn Investment Group purchased a new stake in shares of Incyte during the third quarter worth $30,000. R Squared Ltd acquired a new stake in Incyte during the fourth quarter valued at $30,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Incyte in the third quarter valued at about $33,000. Finally, Groupama Asset Managment increased its position in Incyte by 11.4% in the 3rd quarter. Groupama Asset Managment now owns 59,597 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 6,105 shares during the last quarter. 96.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on INCY. Wells Fargo & Company lifted their price target on Incyte from $68.00 to $70.00 and gave the company an “equal weight” rating in a report on Thursday, December 19th. StockNews.com cut shares of Incyte from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 12th. William Blair restated an “outperform” rating on shares of Incyte in a research note on Friday, December 13th. Oppenheimer lifted their price objective on shares of Incyte from $81.00 to $82.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Finally, JPMorgan Chase & Co. increased their target price on shares of Incyte from $65.00 to $71.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, Incyte currently has a consensus rating of “Hold” and a consensus price target of $75.25.

Insider Transactions at Incyte

In other news, insider Thomas Tray sold 650 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $70.64, for a total transaction of $45,916.00. Following the sale, the insider now directly owns 23,962 shares in the company, valued at approximately $1,692,675.68. The trade was a 2.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Steven H. Stein sold 12,352 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $72.69, for a total value of $897,866.88. Following the completion of the transaction, the executive vice president now owns 66,967 shares of the company’s stock, valued at $4,867,831.23. The trade was a 15.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 19,695 shares of company stock worth $1,444,356. 17.60% of the stock is currently owned by company insiders.

Incyte Stock Up 0.9 %

Shares of INCY stock opened at $72.05 on Monday. Incyte Co. has a 12 month low of $50.35 and a 12 month high of $83.95. The company has a quick ratio of 1.94, a current ratio of 1.97 and a debt-to-equity ratio of 0.01. The firm has a market cap of $13.94 billion, a PE ratio of 266.87, a price-to-earnings-growth ratio of 0.41 and a beta of 0.70. The stock has a 50 day moving average of $71.24 and a 200-day moving average of $69.52.

Incyte (NASDAQ:INCY) last announced its earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.48). Incyte had a return on equity of 0.05% and a net margin of 0.77%. On average, equities analysts predict that Incyte Co. will post 4.86 EPS for the current year.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.